Rivian plans to open U.K. tech office
"Our connected vehicles improve over time through over-the-air updates-and the work the team will do in the U.K. will accelerate our plans and ensure our vehicles remain one of the most technologically advanced and appealing on the road," James Philbin, Rivian vice president of autonomy and AI, said in a statement.
The work at the new London office is expected to build on the Rivian Autonomy Platform, the driver-assist sensor and computing suite that debuted with what the automaker calls its "second-generation" models. These are the updated versions of the R1S and R1T that debuted for the 2025 model year looking the same outside, but with numerous hardware changes underneath.
Rivian's most sophisticated driver-assist system currently allows for hands-free driving as long as drivers keep their eyes on the road, but the automaker believes it can achieve higher levels of automation by leveraging data collected from the growing fleet of newer vehicles. Rivian hopes to construct what it calls a "Large Driving Model" that can understand "complex driving scenarios," paving the way for increased automation.
Back in the U.S., Rivian also recently announced a new East Coast headquarters in Atlanta, not far from the automaker's planned second factory. That $5 billion project was announced in 2021, initially targeting a 2024 opening, but construction was later paused, pushing back the opening to 2027 and then 2028.
Late last year, Rivian was awarded a $6.4 billion conditional loan from the federal government that could be crucial to funding the plant's completion. A $5.8 billion joint venture with the Volkswagen Group, which will give the German automotive behemoth access to Rivian's zonal electrical architecture and software, should also help put the company on the firmer financial footing as it undertakes the launch of its lower-priced R2 electric SUV.
For now, though, things are still a bit tenuous. At the end of last month, Rivian laid off 140 employees, representing about 1% of its workforce, although they were reportedly encouraged to apply at other open positions within the company.
Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jefferies Upgrade Varonis Systems from Hold to Buy, Raises PT to $65
Varonis Systems, Inc. (NASDAQ:VRNS) is one of the Best Cybersecurity Stocks to Buy Under $100. On July 24, Jefferies upgraded Varonis Systems, Inc. (NASDAQ:VRNS) stock from Hold to Buy, raising its price target from $50 to $65. Joseph Gallo from Jefferies raised the rating and price target on VRNS as the analysts believe cybersecurity spend will remain robust and continue to hold a steady percentage of software budgets in the coming years. Varonis Systems offers small-cap exposure to AI in the space. During Q2 2025, the company saw a notable increase in SaaS revenue, growing significantly to $105.9 million from $44.8 million year-over-year. VRNS remains one of Gallo's favorite stocks for the second half of 2025. welcomia/ Gallo also pointed out that Varonis is well-positioned to address the increasingly important data governance market as generative AI adoption materializes. The SaaS revenue growth during Q2 is a major indicator of where the company is heading. Varonis Systems, Inc. (NASDAQ:VRNS) is a data security company that offers a cloud-native data security platform. The company's system discovers and classifies critical data, removes exposures, and detects advanced threats with AI-powered automation. While we acknowledge the potential of VRNS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
3 Penny Stocks With Market Caps Larger Than $10M To Watch
As major U.S. indexes continue their upward trajectory, buoyed by strong corporate earnings and resilient economic data, investors are exploring various avenues for potential growth. Penny stocks, though an older term in the investment lexicon, remain relevant as a category that encompasses smaller or newer companies with lower price points. When these stocks are backed by robust financials and solid fundamentals, they can present unique opportunities for growth that might be overlooked in more traditional investment sectors. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.66 $640.14M ★★★★★★ CuriosityStream (CURI) $4.59 $259.69M ★★★★★★ WM Technology (MAPS) $0.9048 $157.25M ★★★★★★ Tuniu (TOUR) $0.9326 $96.34M ★★★★★★ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.8906 $6.51M ★★★★★★ Lifetime Brands (LCUT) $4.44 $103.55M ★★★★★☆ Resources Connection (RGP) $4.98 $169.03M ★★★★★★ TETRA Technologies (TTI) $3.91 $508.34M ★★★★★★ Tandy Leather Factory (TLF) $3.45 $30.22M ★★★★★★ Click here to see the full list of 413 stocks from our US Penny Stocks screener. Here's a peek at a few of the choices from the screener. MediciNova Simply Wall St Financial Health Rating: ★★★★★★ Overview: MediciNova, Inc. is a biopharmaceutical company that develops novel small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $65.23 million. Operations: MediciNova, Inc. currently does not report any revenue segments. Market Cap: $65.23M MediciNova, Inc., a pre-revenue biopharmaceutical company with a market cap of US$65.23 million, is advancing its clinical pipeline despite financial challenges. The company remains debt-free and has sufficient cash runway for over three years. Recent updates highlight nearing completion of key trials for MN-166 and MN-001, targeting serious diseases like ALS and fatty liver disease. Although unprofitable with net losses reported at US$2.86 million in Q1 2025, MediciNova's seasoned management and board offer stability as it navigates the volatile penny stock landscape while holding Orphan Drug Designations for several treatments from the FDA and EU EMA. Click here and access our complete financial health analysis report to understand the dynamics of MediciNova. Understand MediciNova's earnings outlook by examining our growth report. Vasta Platform Simply Wall St Financial Health Rating: ★★★★★★ Overview: Vasta Platform Limited offers educational printed and digital solutions to private schools in Brazil's K-12 sector, with a market cap of $330.47 million. Operations: The company generates revenue through its Educational Services segment, specifically in Education & Training Services, amounting to R$1.64 billion. Market Cap: $330.47M Vasta Platform Limited, with a market cap of $330.47 million, operates in Brazil's K-12 educational sector and has recently become profitable, though its earnings are forecast to decline by an average of 55.2% annually over the next three years. Trading at a value below its estimated fair value and compared to peers, Vasta's financial health is supported by satisfactory debt levels and interest coverage. However, recent results show a net loss of R$3.27 million for Q1 2025 against revenue declines from the previous year. Management experience remains unclear while one-off gains have impacted past earnings quality. Unlock comprehensive insights into our analysis of Vasta Platform stock in this financial health report. Gain insights into Vasta Platform's future direction by reviewing our growth report. Hugoton Royalty Trust Simply Wall St Financial Health Rating: ★★★★★★ Overview: Hugoton Royalty Trust operates as an express trust in the United States with a market cap of $14.40 million. Operations: The trust's revenue is derived from its Oil & Gas - Exploration & Production segment, totaling $0.01 million. Market Cap: $14.4M Hugoton Royalty Trust, with a market cap of US$14.40 million, operates in the oil and gas sector but remains pre-revenue with earnings for Q1 2025 at just US$2,407. The trust is unprofitable yet has managed to reduce losses over five years by 28.4% annually. Despite its debt-free status and stable shareholder base without recent dilution, the stock's high volatility poses risks for investors. Recent changes include appointing Grant Thornton LLP as the new auditor after dismissing PwC and experiencing delays in SEC filings, reflecting potential operational challenges amidst an already unstable financial position. Jump into the full analysis health report here for a deeper understanding of Hugoton Royalty Trust. Understand Hugoton Royalty Trust's track record by examining our performance history report. Make It Happen Navigate through the entire inventory of 413 US Penny Stocks here. Want To Explore Some Alternatives? The end of cancer? These 25 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MNOV VSTA and HGTX.U. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
6 hours ago
- Yahoo
Jim Cramer Expresses Shock Over Stanley Black & Decker's Weak Quarter
Stanley Black & Decker, Inc. (NYSE:SWK) is one of the stocks Jim Cramer recently talked about. During the episode, Cramer discussed the company's earnings in light of tariffs. He said: 'Oh, and if that wasn't enough, Stanley Black & Decker, another name, look in your house, you've got these, really, just whoa, it shocked me. A weak consumer who seems to have backed away from do-it-yourself projects, coupled with inevitable $800 million tariff hit as the company imports a huge amount of product from China and the so-called reassuring safe haven of Mexico, it took my breath away. bluebay/ Stanley Black & Decker (NYSE:SWK) develops and manufactures tools, equipment, and engineered solutions, including power tools, hand tools, lawn and garden products, and fastening systems. The company's products have applications across construction, automotive, aerospace, and manufacturing sectors. While we acknowledge the potential of SWK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
